Payment overview · 2025
General Payments
$1,282.76
72 reported records · 23 companies
Healthcare provider profile · identity verified
Robert A Cook, MD
Allopathic & Osteopathic Physicians|Family Medicine · PLANO, TX · NPI 1568407690
Verified facts
What the public records show
CMS Open Payments records show Robert A Cook, MD received $1,282.76 in general payments during 2025 across 72 reported records.
ABBVIE INC. accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Trelegy Ellipta, Viberzi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Viberzi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $199.55 | 15.6% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $182.69 | 14.2% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $108.13 | 8.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $89.30 | 7.0% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $81.61 | 6.4% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.17 | 5.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $59.52 | 4.6% | 3 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $58.16 | 4.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.68 | 4.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.65 | 3.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.51 | 3.8% | 3 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $44.89 | 3.5% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $33.48 | 2.6% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.30 | 2.2% | 2 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $24.67 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.13 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.41 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.16 | 1.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.96 | 1.5% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.12 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.68 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.62 | 1.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.37 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,282.76 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $182.69 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $112.76 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $81.61 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $73.28 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.28 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.07 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59.52 | 3 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $58.16 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.56 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $53.57 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $53.06 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.68 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.54 | 3 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $44.89 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $35.33 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $33.48 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $33.48 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $33.48 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.30 | 2 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $11.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 33 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VIBERZI viberzi |
2025 | Viberzi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
81 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 344 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 241 | 88 |
| Alprazolam | Alprazolam | 236 | 74 |
| Meloxicam | Meloxicam | 220 | 94 |
| Azithromycin | Azithromycin | 219 | 175 |
| Lisinopril | Lisinopril | 172 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 56 |
| Losartan Potassium | Losartan Potassium | 160 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 38 |
| Metformin Hcl | Metformin Hcl | 148 | 54 |
| Omeprazole | Omeprazole | 148 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 143 | 43 |
| Gabapentin | Gabapentin | 138 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 52 |
| Temazepam | Temazepam | 119 | 30 |
| Simvastatin | Simvastatin | 108 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 69 |
| Potassium Chloride | Potassium Chloride | 85 | 29 |
| Clonazepam | Clonazepam | 84 | 22 |
| Lorazepam | Lorazepam | 84 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 27 |
| Glipizide | Glipizide | 81 | 28 |
| Synthroid | Levothyroxine Sodium | 81 | 29 |
| Prednisone | Prednisone | 72 | 43 |
| Sertraline Hcl | Sertraline Hcl | 71 | 25 |
| Levofloxacin | Levofloxacin | 69 | 60 |
| Diazepam | Diazepam | 68 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | 26 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 65 | 14 |
| Tramadol Hcl | Tramadol Hcl | 65 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 41 |
| Methylprednisolone | Methylprednisolone | 63 | 52 |
| Trazodone Hcl | Trazodone Hcl | 61 | 24 |
| Allopurinol | Allopurinol | 60 | 21 |
| Spironolactone | Spironolactone | 60 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 27 |
| Valacyclovir | Valacyclovir Hcl | 59 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 32 |
| Furosemide | Furosemide | 56 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 11 |
| Bupropion Xl | Bupropion Hcl | 50 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 44 |
| Atenolol | Atenolol | 49 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 22 |
| Montelukast Sodium | Montelukast Sodium | 47 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 19 |
| Glipizide Er | Glipizide | 44 | 17 |
| Ozempic | Semaglutide | 44 | 12 |
| Azelastine Hcl | Azelastine Hcl | 42 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 14 |
| Carvedilol | Carvedilol | 41 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 41 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 12 |
| Ezetimibe | Ezetimibe | 38 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 12 |
| Estradiol | Estradiol | 37 | 12 |
| Fluconazole | Fluconazole | 36 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 16 |
| Metronidazole | Metronidazole | 34 | 29 |
| Mupirocin | Mupirocin | 34 | 26 |
| Clonidine Hcl | Clonidine Hcl | 33 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Eliquis | Apixaban | 33 | 15 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Nabumetone | Nabumetone | 33 | 15 |
| Pregabalin | Pregabalin | 33 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 12 |
| Naproxen | Naproxen | 32 | 13 |
| Jardiance | Empagliflozin | 30 | 12 |
| Promethazine Hcl | Promethazine Hcl | 30 | 15 |
| Valsartan | Valsartan | 30 | 13 |
| Celecoxib | Celecoxib | 29 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 24 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 19 |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Clarithromycin | Clarithromycin | 24 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 21 |
| Finasteride | Finasteride | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Viberzi | Eluxadoline | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Frovatriptan Succinate | Frovatriptan Succinate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,282.76 · 72 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, BEXSERO, CAPLYTA, CAPVAXIVE, CONTRAVE, Cologuard Collection Kit, ELIQUIS, EVENITY, Flector, JARDIANCE, Kerendia, LEQVIO, Licart, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Prospera, QULIPTA, Quviviq, REPATHA, REXULTI, SHINGRIX, Symbravo, TRELEGY ELLIPTA, Tirosint, Tlando, UBRELVY, VENASEAL, VIBERZI, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error